Demant A/S (OTCMKTS:WILYY) Reaches New 1-Year High – Still a Buy?

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) shares reached a new 52-week high on Wednesday . The stock traded as high as $21.87 and last traded at $21.87, with a volume of 451 shares. The stock had previously closed at $19.25.

Analyst Ratings Changes

A number of research firms have recently commented on WILYY. Zacks Research raised Demant A/S to a “hold” rating in a research note on Friday, June 26th. Morgan Stanley raised Demant A/S from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, June 23rd. UBS Group lowered Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Sanford C. Bernstein lowered Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Demant A/S has a consensus rating of “Moderate Buy”.

Demant A/S Trading Up 5.9%

The business has a 50-day simple moving average of $20.06 and a two-hundred day simple moving average of $17.19. The company has a debt-to-equity ratio of 1.65, a current ratio of 1.36 and a quick ratio of 1.00.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.